Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is exhibiting promising outcomes in early patient studies. Ongoing inquiry https://cheapbookmarking.com/story21260051/retatrutide-emerging-studies-and-potential-medical-applications